# PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

> **NCT03064854** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 111 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** PDR001
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Canakinumab

## Key facts

- **NCT ID:** NCT03064854
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-24
- **Primary completion:** 2021-07-28
- **Final completion:** 2021-07-28
- **Target enrollment:** 111 (ACTUAL)
- **Why stopped:** Recruitment halted prematurely due to competitive landscape for lung cancer therapies
- **Last updated:** 2022-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03064854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03064854, "PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03064854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*